Posts

Showing posts with the label tenofovir

a couple more drug company shenanigans

  the NY Times had another article by Rebecca Robbins on drug company shenanigans, this one on the delayed release of a superior form of tenofovir in the pursuit of profit (see  https://www.nytimes.com/2023/07/22/business/gilead-hiv-drug-tenofovir.html?smid=nytcore-ios-share&referringSource=articleShare  ).   Details : -- Gilead Sciences developed tenofovir disoproxyl fumarate (TDF), which became available in 2001 and was a game-changer for HIV treatment, the single best med at that time. it also was an excellent treatment for chronic hepatitis B infection -- unfortunately, there were a few important adverse effects well-known at the time: kidney failure and osteoporosis -- tenofovir alafenamide (TAF) was initially approved in 2016, as an upgrade, with similar benefits to TDF but significantly fewer renal or bone problems (TAF has much lower plasma concentrations than TDF)     But: -- in 2004, Gilead was developing a "next generation prodrug of ten...

addendum/reply to HIV PrEP: cabotegravir shines

  Here is email form Albert Liu (forwarded with his permission), who was involved in the study, with link to FDA application for CAB approval and comment (not available to review) that study in a small trial of cis-gender women at high risk in Africa had dramatic protection from (89%) with CAB over TDF/FTC!!!   geoff   --------   Hi Geoff,   Thanks for your post about cabotegravir for PrEP! (we were one of the sites conducting the HPTN 083 trial)   I did want to let you know that a sister trial HPTN 084 was recently stopped early with similar findings of superiority of CAB over TDF/FTC in cisgender women in Africa:   https://www.nih.gov/news-events/news-releases/nih-study-finds-long-acting-injectable-drug-prevents-hiv-acquisition-cisgender-women   https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women ...